What Pertussis Mortality Rates Make Maternal Acellular Pertussis Immunization Cost-Effective in Low- and Middle-Income Countries? A Decision Analysis | Zendy

Louise B. Russell | Zendy; Sri Ram Pentakota | Zendy; Cristiana M. Toscano | Zendy; Ben Cosgriff | Zendy; Anushua Sinha | Zendy

Open Access

What Pertussis Mortality Rates Make Maternal Acellular Pertussis Immunization Cost-Effective in Low- and Middle-Income Countries? A Decision Analysis

Author(s) -

Louise B. Russell,

Sri Ram Pentakota,

Cristiana M. Toscano,

Ben Cosgriff,

Anushua Sinha

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw558

Subject(s) - medicine , infant mortality , vaccination , per capita , pertussis vaccine , immunization , child mortality , gross domestic product , pediatrics , cost effectiveness , mortality rate , environmental health , demography , population , immunology , economic growth , economics , risk analysis (engineering) , antigen , sociology

Despite longstanding infant vaccination programs in low- and middle-income countries (LMICs), pertussis continues to cause deaths in the youngest infants. A maternal monovalent acellular pertussis (aP) vaccine, in development, could prevent many of these deaths. We estimated infant pertussis mortality rates at which maternal vaccination would be a cost-effective use of public health resources in LMICs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research